dc.contributor.author | Rosa Garrido, Manuel | |
dc.contributor.author | Ceballos Castillo, Laura | |
dc.contributor.author | Alonso Lecue, Pilar | |
dc.contributor.author | Abraira Meriel, Cristina | |
dc.contributor.author | Delgado Villar, María Dolores | |
dc.contributor.author | Gandarillas Solinís, Alberto | |
dc.contributor.other | Universidad de Cantabria | es_ES |
dc.date.accessioned | 2016-01-27T11:19:25Z | |
dc.date.available | 2016-01-27T11:19:25Z | |
dc.date.issued | 2012-06-19 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | http://hdl.handle.net/10902/7971 | |
dc.description.abstract | CTCF is a ubiquitous epigenetic regulator that has been proposed as a master keeper of chromatin organisation. CTCF-like,
or BORIS, is thought to antagonise CTCF and has been found in normal testis, ovary and a large variety of tumour cells. The
cellular function of BORIS remains intriguing although it might be involved in developmental reprogramming of gene
expression patterns. We here unravel the expression of CTCF and BORIS proteins throughout human epidermis. While CTCF
is widely distributed within the nucleus, BORIS is confined to the nucleolus and other euchromatin domains. Nascent RNA
experiments in primary keratinocytes revealed that endogenous BORIS is present in active transcription sites. Interestingly,
BORIS also localises to interphase centrosomes suggesting a role in the cell cycle. Blocking the cell cycle at S phase or
mitosis, or causing DNA damage, produced a striking accumulation of BORIS. Consistently, ectopic expression of wild type
or GFP- BORIS provoked a higher rate of S phase cells as well as genomic instability by mitosis failure. Furthermore, downregulation
of endogenous BORIS by specific shRNAs inhibited both RNA transcription and cell cycle progression. The results
altogether suggest a role for BORIS in coordinating S phase events with mitosis. | es_ES |
dc.description.sponsorship | This study was supported by the Instituto de Salud Carlos III-Fondo de Investigaciones Sanitarias (ISCIII-FIS; National Grants, Spain): FIS-PI08/0829, FIS-PI11/00397 and Red Temática de Investigación Cooperativa en Cáncer-RTICC-RD06/0020/017 (MDD); FIS-PI08/0890, FIS-PI11/02070 and Programa Regiones Emergentes-EMER (AG); by the Société Française de Dermatologie (SFD, France; AG); and by a co-operative grant from Universidad de Cantabria-Fundación Marqués de Valdecilla-IFIMAV (Cantabria, Spain; Javier León-AG). MRG was recipient of a fellowship from University of Cantabria. Both MRG and PA were also funded by Fundación Leonardo Torres Quevedo and Fundación Marqués de Valdecilla-IFIMAV. AG is ‘on leave’ at the Institut National de la Santé et de la Recherche Médicale (INSERM, France). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | |
dc.format.extent | 15 p. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Public Library of Science | es_ES |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | PLoS One, 2012, 7(6), e39371 | es_ES |
dc.title | A cell cycle role for the epigenetic factor CTCF-L/BORIS | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.identifier.DOI | 10.1371/journal.pone.0039371 | |
dc.type.version | publishedVersion | es_ES |